Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options
The advent of immunotherapy has revolutionized cancer treatment. Prostate cancer has an immunosuppressive microenvironment and a low tumor mutation burden, resulting in low neoantigen expression. The consensus was that immunotherapy would be less effective in prostate cancer. However, recent studies have reported that prostate cancer does have a high number of DNA damage and repair gene defects. Immunotherapies that have been tested in prostate cancer so far have been mainly vaccines and checkpoint inhibitors. A combination of genomically targeted therapies, with approaches to alleviate immune response and thereby make the tumor microenvironment immunologically hot, is promising.
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Dimple Chakravarty, Li Huang, Matthew Kahn, Ashutosh K. Tewari Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Gastroschisis Repair | Genetics | Immunotherapy | Prostate Cancer | Study | Urology & Nephrology | Vaccines